Support Your Metabolism with Clinically-Studied Ingredients

Mitolyn — 6 plant-based nutrients to boost mitochondrial health, energy & natural fat burning.

★★★★★ 127,000+ customers · 90-day money-back guarantee

Dr. Anastassios Pittas, MD

Endocrinology, Diabetes & Metabolism Boston, MA Male

NPI: 1508976036

Total Payments

$1,483

2024 Payments

$1,483

Companies

Transactions

Medicare Patients

541

Medicare Billing

$43,472

Payment Breakdown by Category

Research$1,483 (100.0%)

Payments by Nature

Nature of Payment	Amount	Transactions	Share
Unspecified	$1,483	13	100.0%

Top Paying Companies

Company	Total	Records	Latest Year
ABBVIE INC.	$1,483	13	$0 (2024)

Payment History by Year

Year	Amount	Transactions	Top Company
2024	$1,483	13	ABBVIE INC. ($1,483)

All Payment Transactions

13 individual payment records from CMS Open Payments

Date	Company	Product	Nature	Form	Amount	Type
04/12/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$69.00	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/12/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$50.54	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/12/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$37.50	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$226.86	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$125.05	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$70.25	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$50.54	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$37.50	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/11/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$25.00	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/10/2024	ABBVIE INC.	—	—	In-kind items and services	$400.00	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
04/10/2024	ABBVIE INC.	ARMOUR THYROID (Drug)	—	In-kind items and services	$226.86	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism • Category: THYROID
04/10/2024	ABBVIE INC.	—	—	In-kind items and services	$130.41	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism
04/10/2024	ABBVIE INC.	—	—	In-kind items and services	$33.98	Research
Study: A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism

Research Studies & Clinical Trials

Study Name	Company	Amount	Records
A Phase 2/3 Multicenter, Double Blinded, Randomized, Dose-conversion, Active Control Study Examining the Efficacy and Safety of Armour Thyroid Compared to Synthetic T4 for the Treatment of Adults With Primary Hypothyroidism	ABBVIE INC.	$1,483	13

Medicare Billing by Year

Year	Procedures	Beneficiaries	Services	Submitted	Medicare Paid
2023	4	123	183	$46,760	$10,092
2022	3	132	178	$49,908	$10,294
2021	5	148	242	$60,583	$13,814
2020	5	138	183	$43,816	$9,272

Total Patients

541

Total Services

786

Medicare Billing

$43,472

Procedure Codes

All Medicare Procedures & Services

17 procedure records from CMS Medicare Utilization

HCPCS	Description	Setting	Year	Patients	Services	Charges	Medicare Paid	Ratio
99214	Established patient office or other outpatient visit, 30-39 minutes	Facility	2023	49	74	$28,199	$5,727	20.3%
99213	Established patient office or other outpatient visit, 20-29 minutes	Facility	2023	28	37	$9,963	$1,953	19.6%
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	Facility	2023	28	43	$5,332	$1,229	23.0%
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	Facility	2023	18	29	$3,266	$1,183	36.2%
99214	Established patient office or other outpatient visit, 30-39 minutes	Facility	2022	63	91	$34,193	$6,881	20.1%
99213	Established patient office or other outpatient visit, 20-29 minutes	Facility	2022	35	41	$10,787	$2,030	18.8%
95251	Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report	Facility	2022	34	46	$4,928	$1,383	28.1%
99214	Established patient outpatient visit, total time 30-39 minutes	Facility	2021	54	91	$32,578	$7,037	21.6%
99221	Initial hospital inpatient care, typically 30 minutes per day	Facility	2021	23	23	$7,705	$1,947	25.3%
99213	Established patient outpatient visit, total time 20-29 minutes	Facility	2021	26	34	$8,296	$1,943	23.4%
99231	Subsequent hospital inpatient care, typically 15 minutes per day	Facility	2021	23	58	$7,540	$1,838	24.4%
95251	Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours	Facility	2021	22	36	$4,464	$1,049	23.5%
99214	Established patient office or other outpatient, visit typically 25 minutes	Facility	2020	65	89	$30,080	$5,478	18.2%
99443	Physician telephone patient service, 21-30 minutes of medical discussion	Facility	2020	19	23	$2,898	$1,384	47.8%
95251	Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours	Facility	2020	25	29	$3,596	$863.39	24.0%
99213	Established patient office or other outpatient visit, typically 15 minutes	Facility	2020	18	21	$4,512	$832.57	18.5%
99231	Subsequent hospital inpatient care, typically 15 minutes per day	Facility	2020	11	21	$2,730	$713.31	26.1%

About Dr. Anastassios Pittas, MD

Dr. Anastassios Pittas, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1508976036.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anastassios Pittas, MD has received a total of $1,483 in payments from pharmaceutical and medical device companies, with $1,483 received in 2024. These payments were reported across 13 transactions from 1 company. The most common payment nature is "" ($1,483).

As a Medicare-enrolled provider, Pittas has provided services to 541 Medicare beneficiaries, totaling 786 services with total Medicare billing of $43,472. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.

16,000 Woodworking Plans

Step-by-step blueprints for any project. Beginner to expert.

Detailed schematics Cutting lists & materials Lifetime access — $67

★★★★★ 60-day guarantee

Get Instant Access

Practice Information

Specialty Endocrinology, Diabetes & Metabolism
Other Specialties Diabetes & Metabolism
Location Boston, MA
Active Since 08/30/2006
Last Updated 07/08/2007
Taxonomy Code 207RE0101X
Entity Type Individual
NPI Number 1508976036

Products in Payments

ARMOUR THYROID (Drug) $919.10

Explore

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.